Mostly preclinical

Can peptides heal my injury faster?

This is the most popular reason people look into peptides and the widest gap between claims and evidence. BPC-157 and TB-500 show consistent, impressive tendon and ligament healing in rodents — with almost no controlled human data.

Who this applies to

Problems people bring to this category

Chronic tendinopathy (Achilles, patellar, rotator cuff, elbow)
Ligament sprains and post-surgical recovery
Osteoarthritis-related joint pain
Muscle strains and slow soft-tissue healing

Compounds studied

Peptides used for joints, tendons & injury recovery

BPC-157

Preclinical

Accelerates tendon-to-bone and ligament healing across multiple independent rodent models; angiogenic and cytoprotective mechanisms.

Find BPC-157 at a tested supplier

TB-500

Phase II

Thymosin β-4 fragment promoting cell migration and angiogenesis; human trials exist for wounds and cardiac repair, not sports injury.

Find TB-500 at a tested supplier

GHK-Cu

Phase II

Stimulates collagen and remodelling gene expression; best-evidenced topically rather than systemically.

Find GHK-Cu at a tested supplier

Honest reading

What the evidence actually shows

Animal healing models used doses far above what human users typically take, and rodent tendon biology heals differently from human tendon.
No adequately powered randomised human trial of BPC-157 for tendinopathy has been published.
Reported benefit in humans is anecdotal and confounded by the natural course of tendon healing plus concurrent rehab.

Expectation setting

What peptides will not do here

It will not replace loading-based rehabilitation, which is the only well-proven tendinopathy treatment.
It cannot regrow a fully ruptured tendon or repair structural instability.
Long-term safety, including any effect on existing tumours, is unstudied in humans.

Sources